Galectin Therapeutics Inc financial data

Symbol
GALT on Nasdaq
Industry
Pharmaceutical Preparations
Location
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA
State of incorporation
Nevada
Fiscal year end
December 31
Former names
PRO PHARMACEUTICALS INC (to 5/26/2011)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 191 % +9.77%
Debt-to-equity -136 % +7.51%
Return On Equity 65.3 % -36.5%
Return On Assets -170 % +15%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.3M shares +4.53%
Common Stock, Shares, Outstanding 62.3M shares +4.53%
Entity Public Float 63M USD +6.78%
Common Stock, Value, Issued 62K USD +5.09%
Weighted Average Number of Shares Outstanding, Basic 62.2M shares +4.45%
Weighted Average Number of Shares Outstanding, Diluted 62.2M shares +4.45%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 33.8M USD +6.46%
General and Administrative Expense 5.84M USD -7.68%
Operating Income (Loss) -39.7M USD -4.11%
Nonoperating Income (Expense) -4.62M USD -161%
Net Income (Loss) Attributable to Parent -44.3M USD -11.1%
Earnings Per Share, Basic -0.79 USD/shares -19.7%
Earnings Per Share, Diluted -0.79 USD/shares -19.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.6M USD +42.5%
Assets, Current 27.3M USD +40.2%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 35K USD -50%
Other Assets, Noncurrent 368K USD -40%
Assets 27.7M USD +37.7%
Accounts Payable, Current 3.7M USD +87.1%
Employee-related Liabilities, Current 865K USD +34.9%
Accrued Liabilities, Current 10.9M USD +37.2%
Liabilities, Current 14.6M USD +46.9%
Operating Lease, Liability, Noncurrent 7K USD -87.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 110M USD +54.2%
Retained Earnings (Accumulated Deficit) -378M USD -14.5%
Stockholders' Equity Attributable to Parent -83.9M USD -58.7%
Liabilities and Equity 27.7M USD +37.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.1M USD -12.2%
Net Cash Provided by (Used in) Financing Activities 10M USD 0%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 62.3M shares +4.53%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.6M USD +42.5%
Deferred Tax Assets, Valuation Allowance 78.4M USD +19.1%
Deferred Tax Assets, Gross 78.4M USD +19.1%
Operating Lease, Liability 44K USD -48.8%
Lessee, Operating Lease, Liability, to be Paid 45K USD -52.1%
Property, Plant and Equipment, Gross 74K USD 0%
Operating Lease, Liability, Current 44K USD +2.33%
Lessee, Operating Lease, Liability, to be Paid, Year Two 18K USD -64.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 18K USD -64.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD -87.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 18K USD
Deferred Tax Assets, Operating Loss Carryforwards 61.4M USD +15.6%
Preferred Stock, Shares Issued 1.24M shares -1.98%
Preferred Stock, Shares Authorized 1.74M shares 0%
Additional Paid in Capital 294M USD +6.15%
Preferred Stock, Shares Outstanding 1.24M shares -1.98%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.42M USD -4.57%
Interest Expense 3.38M USD +167%